Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-$\kappa$B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-$\kappa$B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma